| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.178.4064.984 |
| P953 | full work available at URL | https://syndication.highwire.org/content/doi/10.1126/science.178.4064.984 |
| P698 | PubMed publication ID | 5084666 |
| P2093 | author name string | W. H. Oldendorf | |
| L. Braun | |||
| S. Hyman | |||
| S. Z. Oldendorf | |||
| P2860 | cites work | Transactions of the American Neurological Association | Q692195 |
| Archivos de biologia y medicina experimentales | Q27709097 | ||
| Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard | Q34053885 | ||
| Methadone binding to human plasma albumin | Q43873575 | ||
| Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection | Q51116341 | ||
| Regional blood flow by fractional distribution of indicators | Q74847408 | ||
| P433 | issue | 4064 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | morphine | Q81225 |
| blood–brain barrier | Q221694 | ||
| P304 | page(s) | 984-986 | |
| P577 | publication date | 1972-12-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection | |
| Blood-Brain Barrier: Penetration of Morphine, Codeine, Heroin, and Methadone after Carotid Injection | |||
| P478 | volume | 178 |
| Q94697463 | Q94697463 |
| Q34435478 | 3-Methoxynaltrexone, a selective heroin/morphine-6beta-glucuronide antagonist |
| Q58601391 | A computational strategy for finding novel targets and therapeutic compounds for opioid dependence |
| Q35126056 | A vaccine strategy that induces protective immunity against heroin |
| Q90433914 | Abuse liability of mitragynine assessed with a self-administration procedure in rats |
| Q36768732 | Acute and chronic heroin dependence in mice: contribution of opioid and excitatory amino acid receptors |
| Q43557580 | Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. |
| Q72961537 | An analog of ACTH/MSH (4–9), ORG-2766, reduces cerebral uptake of morphine |
| Q49092610 | An intravenous technique for the measurement of cerebral vascular extraction fraction in the rat. |
| Q48831383 | Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system |
| Q58854577 | Biovector nanoparticles improve antinociceptive efficacy of nasal morphine |
| Q48469492 | Blood-brain barrier equilibration of codeine in rats studied with microdialysis |
| Q48716218 | Blood-to-brain transfer of various oxicams: effects of plasma binding on their brain delivery |
| Q48656199 | Central administration of morphine inhibits brain and liver ornithine decarboxylase activity in neonatal rats: involvement of transcription- and non-transcription-dependent mechanisms |
| Q52139401 | Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells. |
| Q46003086 | Clonidine transport at the mouse blood-brain barrier by a new H+ antiporter that interacts with addictive drugs. |
| Q39765636 | Conditioned taste aversion induced by self-administered drugs: paradox revisited |
| Q39417530 | Confirmation of recent heroin abuse: Accepting the challenge |
| Q52579808 | Current Challenges and Opportunities in Treating Glioblastoma. |
| Q43075987 | Designing Safer Analgesics via μ-Opioid Receptor Pathways |
| Q38001793 | Designing prodrugs for the treatment of Parkinson's disease. |
| Q35892296 | Developing a vaccine against multiple psychoactive targets: a case study of heroin |
| Q45060547 | Development of a Clinically Viable Heroin Vaccine. |
| Q35161471 | Differentiating the rapid actions of cocaine |
| Q37238136 | Drug disposition in the mammalian eye and brain: a comparison of mechanisms |
| Q57677287 | Drug transport across the blood-brain barrier |
| Q44394303 | Effects of heroin and its metabolites on schedule-controlled responding and thermal nociception in rhesus monkeys: sensitivity to antagonism by quadazocine, naltrindole and beta-funaltrexamine |
| Q69542868 | Effects of methadone-HCl on dorsal root ganglia in organotypic culture |
| Q34495190 | Effects of morphine on human pancreatic secretion: studies on pure pancreatic juice |
| Q39667475 | Effects of the neuropeptide DG-AVP on morphine and food self-administration by dependent rhesus monkey |
| Q60451057 | Efficacy of D,L-methadone in the treatment of glioblastoma in vitro |
| Q37196317 | Evidence for the nucleus accumbens as a neural substrate of heroin-induced immune alterations |
| Q39540769 | Evidence of active transport involvement in morphine transport via MDCKII and MDCK-PGP cell lines |
| Q40327837 | Excretion of drugs in human breast milk |
| Q36942846 | First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo |
| Q39358193 | Fundamental reaction pathway and free energy profile for butyrylcholinesterase-catalyzed hydrolysis of heroin |
| Q52291826 | Heroin and morphine: Aversive and analgesic effects in rats |
| Q45340080 | Heroin-assisted treatment in the Netherlands: History, findings, and international context |
| Q50672428 | Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties. |
| Q44856527 | Impact of environmental and genetic factors on codeine analgesia |
| Q42555336 | Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake |
| Q37960529 | Improving the transport of chemotherapeutic drugs across the blood-brain barrier |
| Q35782792 | In vitro blood-brain barrier models: current and perspective technologies |
| Q48454791 | Independent blood-brain barrier transport systems for nucleic acid precursors |
| Q34352413 | Influence of hydrocortisone on the mechanical properties of the cerebral endothelium in vitro |
| Q36479824 | Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance |
| Q48148305 | LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier? |
| Q37219079 | Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats |
| Q61813333 | Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine |
| Q30427348 | Microbubbles coupled to methotrexate-loaded liposomes for ultrasound-mediated delivery of methotrexate across the blood-brain barrier |
| Q33783467 | Microinjection of codeine into the region of the caudal ventral respiratory column suppresses cough in anesthetized cats |
| Q69602745 | Morphine Concentrations and Survival Periods in Acute Heroin Fatalities |
| Q39811218 | Morphine and 5-hydroxytryptamine interactions in rat hypothalamus and pineal body |
| Q72413542 | Morphine, but not diacetyl morphine (heroin), possesses opiate antagonist activity in the mouse vas deferens |
| Q30385033 | Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. |
| Q37028008 | Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine. |
| Q48793216 | On the partition of ampholytes: application to blood-brain distribution |
| Q37364459 | Opiate-agonist induced taste aversion learning in the Fischer 344 and Lewis inbred rat strains: evidence for differential mu opioid receptor activation |
| Q92626719 | Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids |
| Q39285381 | Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain. |
| Q48098914 | P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells |
| Q43537321 | PHARMACOKINETICS In the rat of the hallucinogenic alkaloids harmine and harmaline |
| Q55022470 | Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic. |
| Q26852773 | Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers |
| Q33783748 | Pathways for small molecule delivery to the central nervous system across the blood-brain barrier |
| Q34489836 | Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. |
| Q57374255 | Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein |
| Q33999749 | Permeability changes in the blood-brain barrier: causes and consequences |
| Q38353145 | Permeability of the Blood-Brain Barrier: Molecular Mechanism of Transport of Drugs and Physiologically Important Compounds |
| Q37264538 | Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. |
| Q44302066 | Pharmacokinetic modeling of subcutaneous heroin and its metabolites in blood and brain of mice |
| Q49108658 | Pharmacokinetic-pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats--a microdialysis study |
| Q57677413 | Pharmacokinetics of [3H]Biotin Bound to Different Avidin Analogues |
| Q48716326 | Pharmacological Effects of a Monoclonal Antibody against 6-Monoacetylmorphine upon Heroin-Induced Locomotor Activity and Pharmacokinetics in Mice. |
| Q48638229 | Pharmacological Implications of the Conformation of the Methadone Base |
| Q40139437 | Pharmacosexology Update: Heroin and Sexual Function |
| Q73605651 | Phenotypic and functional assessments of immune status in the rat spleen following acute heroin treatment |
| Q52289054 | Population pharmacokinetics of heroin and its major metabolites. |
| Q44247350 | Possible mechanism involved in the anticonvulsant action of butorphanol in mice |
| Q36383315 | Post heroin dose tissue distribution of 6-monoacetylmorphine (6-MAM) with MALDI imaging |
| Q34129781 | Prescription drug abuse: insight into the epidemic. |
| Q37150860 | Prodrug approaches for CNS delivery |
| Q37193593 | Progress in drug delivery to the central nervous system by the prodrug approach. |
| Q39238906 | Reaction pathways and free energy profiles for cholinesterase-catalyzed hydrolysis of 6-monoacetylmorphine |
| Q52534596 | Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. |
| Q35580984 | Rewarding electrical brain stimulation in rats after peripheral nerve injury: decreased facilitation by commonly abused prescription opioids |
| Q37103059 | Roles of dopaminergic innervation of nucleus accumbens shell and dorsolateral caudate-putamen in cue-induced morphine seeking after prolonged abstinence and the underlying D1- and D2-like receptor mechanisms in rats |
| Q48482517 | Selective changes in the permeability of the blood‐brain barrier after pharmacological or surgical deafferentation |
| Q35681802 | Street drug abuse leading to critical illness |
| Q52317568 | Structurally-Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice. |
| Q49172338 | Study with positron emission tomography of the osmotic opening of the dog blood-brain barrier for quinidine and morphine |
| Q35688659 | Supplemental morphine infusion into the posterior ventral tegmentum extends the satiating effects of self-administered intravenous heroin |
| Q90264061 | Synthesis and Evaluations of Novel Apocynin Derivatives as Anti-Glioma Agents |
| Q53275431 | Tandem DART™ MS Methods for Methadone Analysis in Unprocessed Urine. |
| Q40373095 | The acute disposition of (R)- and (s)-methadone in brain and lung of sheep |
| Q66884851 | The blood-brain barrier |
| Q48394325 | The effect of methadone on fetal brain function |
| Q39433076 | The influence of active transport systems on morphine -6-glucuronide transport in MDCKII and MDCK-PGP cells |
| Q41823871 | The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. |
| Q36329172 | The scientific basis for analgesic use in dentistry |
| Q38478413 | Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions |
| Q28539271 | Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system |
| Q33827984 | Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex |
| Q34239620 | Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo |
| Q81093454 | [The role of morphine-6-glucuronide during longterm administration of morphine.]. |
Search more.